A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.
Status:
RECRUITING
Trial end date:
2024-08-04
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy of different doses of WS016(3g, 6g and 12g) orally administered three times a day for 48 hours (acute treatment phase) vs placebo in the treatment of hyperkalemia, and to evaluate the efficacy of WS016(3g, 6g and 12g) orally administered once daily for 12 days ( maintenance treatment phase) vs placebo in maintaining normokalemia in participants have returned to normokalemia after the acute treatment phase.